CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
DDDr. Dereck Mush, MD, MBA
Feb 4
RegCell
Epigenetic reprogramming of auto-reactive T cells into antigen-specific regulatory T cells.
What they do
RegCell develops a non-genetic epigenetic reprogramming platform that converts pathogenic auto-reactive T cells into stable, antigen-specific regulatory T cells for autoimmune disease and transplant tolerance. The company has raised $66M, including a $44M Series A led by Playground Global and non-dilutive support from Japan AMED.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Cell therapy
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Emeryville, CA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $66M raised
Notable investors: Playground Global.
Also in Pharma & Drug Discovery
Related on The Signal
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
DDDr. Dereck Mush, MD, MBA
Jan 14
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
DDDr. Dereck Mush, MD, MBA
Sep 3The HealthTech Signal
The Top Gene Therapy Breakthroughs of 2026
CRISPR crossed from theory into the clinic. These ten breakthroughs are real, approved and working, and every single one carries the same catch.
DDDr. Dereck Mush, MD, MBA
Jul 5